Ikervis

Ciclosporin, the active ingredient in Ikervis, is a calcineurin inhibitor presented as a 0.1% w/v ophthalmic emulsion for ocular (topical) use. It treats dry eye disease and keratoconjunctivitis sicca in patients whose conventional tear substitutes are insufficient. The formulation is designed for once‑daily administration to improve ocular comfort.

GNH USA supplies Ikervis as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑ready documentation for global distribution.

Ikervis (ciclosporin ophthalmic emulsion) is used to manage ocular surface inflammatory conditions.

- Dry eye disease: reduces ocular surface inflammation and improves tear film stability. - Keratoconjunctivitis sicca: alleviates symptoms by suppressing T‑cell mediated inflammation. - Ocular surface inflammation: provides immunomodulatory effect to restore ocular comfort.

Ikervis may cause ocular and systemic reactions.

Common Side Effects: - Burning or stinging sensation at the application site. - Eye irritation or itching. - Blurred vision shortly after instillation. - Redness of the conjunctiva. - Foreign body sensation. - Mild eye discharge.

Serious or Rare Side Effects: - Ocular infection (bacterial, fungal, or viral). - Allergic reaction with swelling or severe redness. - Increased intra‑ocular pressure. - Corneal ulcer or epithelial defect. - Severe eye pain or vision loss. - Systemic immunosuppression leading to opportunistic infections.

Before using Ikervis, consider the following precautions: - Hypersensitivity: avoid if the patient has known allergy to ciclosporin or any excipients. - Ocular infection: assess and treat active infections prior to initiation. - Intra‑ocular pressure: monitor pressure regularly during treatment. - Contact lens wear: discontinue lenses while using the drops unless advised otherwise. - Pregnancy and lactation: evaluate risk‑benefit as safety data are limited. - Store at room temperature: keep in the original container, protect from light and moisture.

Ikervis may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concomitant topical corticosteroids: may increase risk of ocular hypertension. - Systemic immunosuppressants: combined use can potentiate systemic immunosuppression. - Other calcineurin inhibitors: concurrent use may raise toxicity risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may affect drug absorption. - Antiviral ophthalmic preparations: potential reduction in antiviral efficacy. - Topical anesthetics: may increase local irritation when used together.